JP2022177246A - Composition for external use - Google Patents
Composition for external use Download PDFInfo
- Publication number
- JP2022177246A JP2022177246A JP2022153557A JP2022153557A JP2022177246A JP 2022177246 A JP2022177246 A JP 2022177246A JP 2022153557 A JP2022153557 A JP 2022153557A JP 2022153557 A JP2022153557 A JP 2022153557A JP 2022177246 A JP2022177246 A JP 2022177246A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- minoxidil
- composition
- external use
- pyridoxine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 93
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 84
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 abstract description 63
- 229960003632 minoxidil Drugs 0.000 abstract description 63
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract description 21
- 238000001556 precipitation Methods 0.000 abstract description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 15
- 235000008160 pyridoxine Nutrition 0.000 abstract description 15
- 239000011677 pyridoxine Substances 0.000 abstract description 15
- 150000003839 salts Chemical class 0.000 abstract description 15
- 229940011671 vitamin b6 Drugs 0.000 abstract description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 14
- 239000002253 acid Substances 0.000 abstract description 13
- 239000006210 lotion Substances 0.000 abstract description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 7
- 238000009472 formulation Methods 0.000 abstract description 7
- 239000004310 lactic acid Substances 0.000 abstract description 7
- 235000014655 lactic acid Nutrition 0.000 abstract description 7
- 239000011975 tartaric acid Substances 0.000 abstract description 7
- 235000002906 tartaric acid Nutrition 0.000 abstract description 7
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 abstract description 5
- 229910017604 nitric acid Inorganic materials 0.000 abstract description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract description 4
- 239000011976 maleic acid Substances 0.000 abstract description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000443 aerosol Substances 0.000 abstract description 2
- 239000006071 cream Substances 0.000 abstract description 2
- 230000006866 deterioration Effects 0.000 abstract description 2
- 239000003349 gelling agent Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 230000001256 tonic effect Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 78
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 29
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 29
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 29
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000008213 purified water Substances 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 21
- 230000000699 topical effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 7
- 150000005846 sugar alcohols Polymers 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- -1 arachyl alcohol Chemical compound 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- CAYHVMBQBLYQMT-UHFFFAOYSA-N 2-decyltetradecan-1-ol Chemical compound CCCCCCCCCCCCC(CO)CCCCCCCCCC CAYHVMBQBLYQMT-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- FIPPFBHCBUDBRR-UHFFFAOYSA-N henicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCO FIPPFBHCBUDBRR-UHFFFAOYSA-N 0.000 description 2
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical group N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008609 bushi Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N n-nonadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
本発明は、ミノキシジルを有効成分とする外用組成物に関する。更に詳細には、ピリドキシンを配合したミノキシジル含有外用組成物の適用により生じる可能性のあるミノキシジル由来の析出を抑制する技術に関する。 The present invention relates to an external composition containing minoxidil as an active ingredient. More particularly, it relates to a technique for suppressing minoxidil-derived precipitation that may occur due to the application of a minoxidil-containing topical composition containing pyridoxine.
ミノキシジルは化学名を6-(1-ピペリジニル)-2,4-ピリミジンジアミン-3-オキサイドと称し、育毛剤としての適応が知られており(特許文献1)、優れた育毛・発毛効果を発揮する薬剤として多数の報告がある。
ミノキシジル含有外用組成物は、頭部に長期間にわたって毎日使用するものであるため、使用感においても優れた組成物が求められている。ミノキシジルの濃度を高めた組成物を使用した際、塗布後まれにミノキシジル由来の析出が生じ、フケのように見えることがある。したがって、ミノキシジルを配合した外用組成物において、塗布した後に生じる可能性のあるミノキシジル由来の析出を抑制した組成物が望まれる。
また、ピリドキシンは脂質合成抑制効果があることが報告されており(非特許文献1)、多くの育毛剤に用いられている。
Minoxidil, whose chemical name is 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, is known to be applied as a hair restorer (Patent Document 1), and has excellent hair growth and growth effects. There are many reports as a drug that exerts
Since minoxidil-containing topical compositions are used on the head every day for a long period of time, there is a demand for compositions that are excellent in feeling during use. When a composition with a high concentration of minoxidil is used, minoxidil-derived precipitation rarely occurs after application, and it may look like dandruff. Therefore, in a composition for external use containing minoxidil, a composition that suppresses minoxidil-derived precipitation that may occur after application is desired.
Pyridoxine has also been reported to have a lipid synthesis inhibitory effect (Non-Patent Document 1), and is used in many hair restorers.
本発明は、ピリドキシンを配合したミノキシジル含有外用組成物について、塗布した後に生じる可能性のあるミノキシジル由来の析出を抑制したミノキシジル含有外用組成物を提供することを課題とする。 An object of the present invention is to provide a minoxidil-containing topical composition containing pyridoxine that suppresses minoxidil-derived precipitation that may occur after application.
本発明者らは、上記課題を解決すべく鋭意検討を重ねた結果、ミノキシジル、ピリドキシン、特定の多価アルコール、特定の酸を配合した組成物は、ミノキシジル由来の析出を抑制できることを見出し、本発明を完成するに至った。 The present inventors have made intensive studies to solve the above problems, and as a result, found that a composition containing minoxidil, pyridoxine, a specific polyhydric alcohol, and a specific acid can suppress minoxidil-derived precipitation. I have perfected my invention.
すなわち本発明は、
(1)1)ミノキシジル、2)ピリドキシン及び/又はその塩、3)プロピレングリコール、及び4)リン酸、クエン酸、乳酸、塩酸、酢酸、硫酸、硝酸、酒石酸、及びマレイン酸からなる群から選ばれる少なくとも1種の酸及び/又はこれらの塩を含有するすることを特徴とする外用組成物、
(2)ミノキシジルの濃度が5w/w%以上である(1)に記載の外用組成物、
である。
That is, the present invention
(1) selected from the group consisting of 1) minoxidil, 2) pyridoxine and/or salts thereof, 3) propylene glycol, and 4) phosphoric acid, citric acid, lactic acid, hydrochloric acid, acetic acid, sulfuric acid, nitric acid, tartaric acid, and maleic acid. Composition for external use, characterized in that it contains at least one acid and / or a salt thereof,
(2) The topical composition according to (1), wherein the concentration of minoxidil is 5 w/w% or more;
is.
本発明により、ピリドキシンを配合したミノキシジル含有外用組成物において、塗布した後に生じる可能性のあるミノキシジル由来の析出を抑制することが可能となった。さらに、意外にも、製剤中に沈殿物が生じない、澄明なミノキシジル含有組成物として提供でき、かつピリドキシン及び/またはその塩の経時的な安定性の低下を抑制できる。 INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to suppress minoxidil-derived precipitation that may occur after application in a minoxidil-containing topical composition containing pyridoxine. Furthermore, unexpectedly, it is possible to provide a clear minoxidil-containing composition in which no sediment occurs in the formulation, and to suppress deterioration in the stability of pyridoxine and/or a salt thereof over time.
本発明によれば、ミノキシジル、ピリドキシン及び/又はその塩、プロピレングリコール、及び特定の酸及び/又はその塩を含有する外用組成物は、塗布した後に生じる可能性のあるミノキシジル由来の析出を抑制し、製剤に沈殿物が生じず、かつピリドキシンの安定性の低下を抑制したものとなる。 According to the present invention, an external composition containing minoxidil, pyridoxine and/or salts thereof, propylene glycol, and a specific acid and/or salts thereof suppresses minoxidil-derived precipitation that may occur after application. , the formulation does not form a precipitate and suppresses a decrease in the stability of pyridoxine.
本発明の外用組成物において用いるミノキシジルは、通常医薬品に用いられる品質のものを適宜使用することができる。また、本発明によれば、ミノキシジルの含有量が多くなるにつれ製剤塗布後に生じる可能性のある析出の課題が大きくなるため、外用組成物中におけるミノキシジルの濃度が高いほど、本発明を実施する意義が大きい。具体的には、本発明の外用組成物中1w/w%以上であり、さらに好ましくは3w/w%以上であり、さらにより好ましくは5w/w%以上である。 As for minoxidil used in the composition for external use of the present invention, minoxidil of a quality commonly used in pharmaceuticals can be appropriately used. In addition, according to the present invention, the higher the minoxidil content, the greater the problem of precipitation that may occur after application of the formulation. is large. Specifically, it is 1 w/w% or more, more preferably 3 w/w% or more, and still more preferably 5 w/w% or more in the composition for external use of the present invention.
本発明の外用組成物における特定の酸及び/又はその塩は、沈殿のない澄明な製剤が得られるという本発明の効果の観点から、リン酸、クエン酸、乳酸、塩酸、酢酸、硫酸、硝酸、酒石酸、マレイン酸、又はこれらの塩であり、好ましくはリン酸、クエン酸、乳酸、酒石酸である。これらの酸及び/又はこれらの塩は、本発明の外用組成物の液性を7以下に調節する成分であり、いずれも無機酸又はその塩もしくは炭素数が6以下の有機酸又はその塩である。本発明の特定の酸及び/又はその塩は、1種又は2種以上組み合わせてもよい。 The specific acids and/or salts thereof in the composition for external use of the present invention are phosphoric acid, citric acid, lactic acid, hydrochloric acid, acetic acid, sulfuric acid, and nitric acid, from the viewpoint of the effect of the present invention that a clear formulation without precipitation is obtained. , tartaric acid, maleic acid, or salts thereof, preferably phosphoric acid, citric acid, lactic acid, or tartaric acid. These acids and/or salts thereof are components for adjusting the liquid properties of the composition for external use of the present invention to 7 or less, and are inorganic acids or salts thereof, or organic acids or salts thereof having 6 or less carbon atoms. be. The specific acids and/or salts thereof of the present invention may be used singly or in combination of two or more.
また、本発明の外用組成物において用いる多価アルコールは、本発明の効果である、塗布した後にミノキシジル由来の析出を生じさせない点からプロピレングリコールである。プロピレングリコールの配合量は、全組成物中好ましくは2~55w/w%であり、より好ましくは5~35w/w%である。本発明の外用組成物中には、本発明の効果を損なわない範囲でプロピレングリコール以外の多価アルコールを含んでもよいが、グリセリン、ポリエチレングリコールは配合しない方が本発明の効果の点から好ましく、プロピレングリコールのみ配合することが本発明の効果の点から最も好ましい。 In addition, the polyhydric alcohol used in the composition for external use of the present invention is propylene glycol because it does not cause precipitation derived from minoxidil after application, which is the effect of the present invention. The blending amount of propylene glycol is preferably 2 to 55 w/w%, more preferably 5 to 35 w/w%, in the total composition. The composition for external use of the present invention may contain a polyhydric alcohol other than propylene glycol as long as it does not impair the effects of the present invention. From the viewpoint of the effect of the present invention, it is most preferable to blend only propylene glycol.
また、本発明の外用組成物は、主薬成分のミノキシジルの安定性、使用時の肌への刺激感、薬物の浸透性、使用感等の点から、そのpHを4.0~9.5の範囲に調整することが好ましく、5.0~7.0の範囲がさらに好ましい。さらに、pHの上限としては、好ましくは6.5未満であり、より好ましくは6.3以下、さらに好ましくは6.1以下である。 In addition, the composition for external use of the present invention has a pH of 4.0 to 9.5 from the viewpoints of the stability of minoxidil, which is the main ingredient, the feeling of irritation to the skin during use, the permeability of the drug, the feeling of use, etc. It is preferable to adjust it within a range, more preferably 5.0 to 7.0. Furthermore, the upper limit of the pH is preferably less than 6.5, more preferably 6.3 or less, still more preferably 6.1 or less.
本発明の外用組成物において用いるピリドキシンの配合量は、本発明の効果の点から外用組成物中0.01~2w/w%が好ましく、0.03~0.1w/w%がより好ましく、0.03~0.05w/w%がさらに好ましい。 The amount of pyridoxine used in the topical composition of the present invention is preferably 0.01 to 2 w/w%, more preferably 0.03 to 0.1 w/w%, in terms of the effects of the present invention. 0.03 to 0.05 w/w% is more preferred.
本発明の外用組成物には、更に必要により高級アルコールを配合することができる。高級アルコールの例としては、炭素数が6~24のジアセトンアルコール、カプロイルアルコール、カプリリルアルコール、カプリルアルコール、ラウリルアルコール、トリデカノール、ミリスチルアルコール、ペンタデカノール、セチルアルコール、ヘキシルデカノール、イソセチルアルコール、セトステアリルアルコール、ヘプタデカノール、ステアリルアルコール、オレイルアルコール、イソステアリルアルコール、オクチルデカノール、ノナデカノール、アラキルアルコール、オクチルドデカノール、ヘンイコサノール、ベヘニルアルコール、デシルテトラデカノールがより好ましく、そのうち、ジアセトンアルコール、ラウリルアルコール、ミリスチルアルコール、セチルアルコール、ヘキシルデカノール、セトステアリルアルコール、ステアリルアルコール、イソステアリルアルコール、オレイルアルコール、アラキルアルコール、オクチルドデカノール、ベヘニルアルコール、デシルテトラデカノールがさらに好ましい。本発明の高級アルコールは、1種又は2種以上組み合わせて使用しても良い。高級アルコールの配合量は、全組成物中0.05~2w/w%が好ましく、0.1~1.5w/w%がより好ましく、更に好ましくは0.25~1.5w/w%である。 The composition for external use of the present invention may further contain a higher alcohol if necessary. Examples of higher alcohols include diacetone alcohol having 6 to 24 carbon atoms, caproyl alcohol, caprylyl alcohol, capryl alcohol, lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, hexyldecanol, isocetyl alcohol, More preferred are cetostearyl alcohol, heptadecanol, stearyl alcohol, oleyl alcohol, isostearyl alcohol, octyldecanol, nonadecanol, arachyl alcohol, octyldodecanol, henicosanol, behenyl alcohol and decyltetradecanol, of which diacetone alcohol, More preferred are lauryl alcohol, myristyl alcohol, cetyl alcohol, hexyldecanol, cetostearyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, arachyl alcohol, octyldodecanol, behenyl alcohol and decyltetradecanol. You may use the higher alcohol of this invention 1 type or in combination of 2 or more types. The blending amount of the higher alcohol is preferably 0.05 to 2 w/w%, more preferably 0.1 to 1.5 w/w%, and still more preferably 0.25 to 1.5 w/w% in the total composition. be.
本発明の外用組成物には、更に必要により低級アルコールや水を配合することができる。低級アルコールとしては、炭素数1~5のものが好ましく、例えばエタノールやイソプロパノールなどが好ましく、これらを組み合わせて使用しても良い。低級アルコールの配合量は、全組成物中20w/w%以上が好ましく、より好ましくは30w/w%以上であり、より好ましくは35w/w%以上であり、更に好ましくは50w/w%以上である。水の配合量は、2~75w/w%が好ましく、より好ましくは5~50w/w%である。 The composition for external use of the present invention may further contain a lower alcohol or water, if necessary. As the lower alcohol, those having 1 to 5 carbon atoms are preferred, such as ethanol and isopropanol, and these may be used in combination. The amount of the lower alcohol is preferably 20 w/w% or more, more preferably 30 w/w% or more, more preferably 35 w/w% or more, and still more preferably 50 w/w% or more in the entire composition. be. The blending amount of water is preferably 2 to 75 w/w%, more preferably 5 to 50 w/w%.
本発明の外用組成物には、更に必要により高級脂肪酸を配合することができる。高級脂肪酸の例としては、炭素数10~22のものが好ましく、例えばイソステアリン酸、オレイン酸、ステアリン酸、カプリン酸、ラウリン酸、ミリスチン酸、パルミチン酸、パルミトレイン酸、リノール酸、リノレン酸、エライジン酸、アラキジン酸、アラキドン酸、ベヘン酸、エイコサペンタエン酸、ドコサヘキサエン酸等が挙げられ、これらを1種又は2種以上組み合わせてもよい。このうち、炭素数18のものが好ましく、特にイソステアリン酸又はオレイン酸が好ましい。高級脂肪酸の配合量は、全組成物中好ましくは0.1~10w/w%であり、より好ましくは1~6w/w%である。 The composition for external use of the present invention may further contain a higher fatty acid if necessary. Examples of higher fatty acids preferably have 10 to 22 carbon atoms, such as isostearic acid, oleic acid, stearic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, linoleic acid, linolenic acid, and elaidic acid. , arachidic acid, arachidonic acid, behenic acid, eicosapentaenoic acid, docosahexaenoic acid and the like, and these may be used singly or in combination of two or more. Among these, those having 18 carbon atoms are preferred, and isostearic acid or oleic acid is particularly preferred. The blending amount of the higher fatty acid is preferably 0.1 to 10 w/w%, more preferably 1 to 6 w/w%, in the total composition.
本発明の外用組成物には、更に必要により界面活性剤を配合することができる。しかしながら、界面活性剤の添加は、使用感やミノキシジルの皮膚吸収に影響を与える可能性があり、本発明の外用組成物では、界面活性剤を配合しなくてもミノキシジルの溶解性を確保できるため、実質的に界面活性剤を含まないものとすることが好ましい。 The composition for external use of the present invention may further contain a surfactant, if necessary. However, the addition of surfactants may affect the feeling of use and skin absorption of minoxidil, and in the composition for external use of the present invention, the solubility of minoxidil can be ensured without blending surfactants. , preferably substantially free of surfactants.
本発明の外用組成物には、上記した各成分の他に、本発明の効果を損なわない範囲で、必要な活性成分や補助成分を加えることができる。本発明のローション剤に添加、配合することが好ましい薬効成分としては、メントール、ビタミンEアセテート、パントテニルエチルエーテル、ヒノキチオール、グリチルレチン酸、塩酸ジフェンヒドラミン、パンテノールから成る群より選ばれた成分が挙げられる。
これら選択成分の添加量は、特に制約はなく、使用感やミノキシジルの安定性あるいは溶剤系組成等を考慮しながら実験的に定めることができる。
In addition to the components described above, the composition for external use of the present invention can contain necessary active ingredients and auxiliary ingredients within a range that does not impair the effects of the present invention. Medicinal ingredients that are preferably added to or blended with the lotion of the present invention include ingredients selected from the group consisting of menthol, vitamin E acetate, pantothenyl ethyl ether, hinokitiol, glycyrrhetinic acid, diphenhydramine hydrochloride, and panthenol. .
The amount of these optional components to be added is not particularly limited, and can be determined experimentally while considering the feel of use, the stability of minoxidil, the composition of the solvent system, and the like.
本発明の外用組成物においては、上記した成分の他、本発明の効果を損なわない範囲で、一般の外用剤に用いられる種々の活性成分や補助成分を配合することができる。例えば、賦形剤、育毛成分(6-ベンジルアミノプリン、アデノシン、ペンタデカン酸グリセリド、何首鳥等)、血管拡張剤(塩化カルプロニウム、ニコチン酸ベンジル、センブリ抽出液、オタネニンジンエキス、チクセツニンジンチンキ、トウガラシチンキ等)、抗ヒスタミン剤(塩酸イソチペンジル等)、抗炎症剤(グアイアズレン等)、角質溶解剤(尿素、サリチル酸等)、殺菌剤(グルコン酸クロルヘキシジン、イソプロピルメチルフェノール、第4級アンモニウム塩、ピロクトンオラミン等)、保湿剤(ヒアルロン酸又はその塩、コンドロイチン硫酸等)、各種動植物(イチイ、ボタンピ、カンゾウ、オトギリソウ、附子、ビワ、カワラヨモギ、コンフリー、アシタバ、サフラン、サンシシ、ローズマリー、セージ、モッコウ、セイモッコウ、ホップ、プラセンタ、ノコギリヤシ、パンプキンシード等)の抽出物、ビタミン類(酢酸レチノール、アスコルビン酸、硝酸チアミン、シアノコバラミン、ビオチン等)、抗酸化剤(ジブチルヒドロキシトルエン、ピロ亜硫酸ナトリウム、トコフェロール、エデト酸ナトリウム、アスコルビン酸、イソプロピルガレート等)、溶解補助剤(アジピン酸ジイソプロピル、ミリスチン酸イソプロピル、各種植物油、各種動物油、アルキルグリセリルエーテル、炭化水素類等)、代謝賦活剤、ゲル化剤(水溶性高分子等)、粘着剤、香料、清涼化剤(ハッカ油、カンフル等)、染料等の通常使用される成分を配合することができる。 In the composition for external use of the present invention, in addition to the above components, various active ingredients and auxiliary components used in general external preparations can be blended within a range that does not impair the effects of the present invention. For example, excipients, hair-growth ingredients (6-benzylaminopurine, adenosine, pentadecanoic acid glyceride, Hekkei bird, etc.), vasodilators (carpronium chloride, benzyl nicotinate, assembly extract, panax ginseng extract, ginseng tincture, Capsicum tincture, etc.), antihistamines (isothipendyl hydrochloride, etc.), anti-inflammatory agents (guaiazulene, etc.), keratolytic agents (urea, salicylic acid, etc.), bactericides (chlorhexidine gluconate, isopropylmethylphenol, quaternary ammonium salts, piroctoneola) min, etc.), moisturizing agents (hyaluronic acid or its salts, chondroitin sulfate, etc.), various animals and plants (yew, botanpi, licorice, hypericum perforatum, Bushi, loquat, artemisia var. , Seymong, hops, placenta, saw palmetto, pumpkin seed, etc.), vitamins (retinol acetate, ascorbic acid, thiamine nitrate, cyanocobalamin, biotin, etc.), antioxidants (dibutyl hydroxytoluene, sodium pyrosulfite, tocopherol, edet) sodium acid, ascorbic acid, isopropyl gallate, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, various vegetable oils, various animal oils, alkyl glyceryl ethers, hydrocarbons, etc.), metabolic activators, gelling agents (highly water-soluble molecules, etc.), adhesives, fragrances, refreshing agents (mint oil, camphor, etc.), dyes, and other commonly used ingredients can be blended.
本発明の外用組成物は、ローション剤、エアゾール剤、トニック剤、クリーム剤、軟膏剤、ゲル剤等の適当な外用組成物とすることができる。このうち、最も好ましい剤型はローション剤である。 The topical composition of the present invention can be a suitable topical composition such as lotions, aerosols, tonics, creams, ointments, gels and the like. Among these, the most preferable dosage form is a lotion.
本発明の外用組成物の調製は、常法に従い、上記各成分を含有することにより調製される。 The composition for external use of the present invention is prepared according to a conventional method by containing each of the above components.
かくして得られる本発明の外用組成物は、頭髪用剤、睫毛用剤、眉毛用剤等の皮膚適用製剤等として使用することができる。 The composition for external use of the present invention thus obtained can be used as a preparation for skin application such as a preparation for hair, a preparation for eyelashes and a preparation for eyebrows.
以下に、実施例、比較例及び試験例を記載し、本発明をさらに具体的に説明するが、本発明はこれら実施例等により何ら制約されるものではない。 EXAMPLES Examples, comparative examples and test examples are given below to describe the present invention in more detail, but the present invention is not limited by these examples.
(実施例1)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、リン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 1)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of phosphoric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(実施例2)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、クエン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.1の外用組成物を得た。
(Example 2)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of citric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.1.
(実施例3)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、乳酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.1の外用組成物を得た。
(Example 3)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of lactic acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.1.
(実施例4)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、塩酸適量、精製水20g適量、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 4)
Minoxidil 5 g, pyridoxine hydrochloride 0.05 g, propylene glycol 15 g, hydrochloric acid appropriate amount, purified water 20 g appropriate amount, ethanol was added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain an external composition having a pH of 6.0.
(実施例5)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、酢酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.1の外用組成物を得た。
(Example 5)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of acetic acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.1.
(実施例6)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、硫酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 6)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of sulfuric acid, 20 g of purified water, and ethanol were added to bring the total amount to 100 g.
(実施例7)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、硝酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 7)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of nitric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(実施例8)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、酒石酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.1の外用組成物を得た。
(Example 8)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of tartaric acid, 20 g of purified water, and ethanol were added to bring the total amount to 100 g.
(実施例9)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、マレイン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 9)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of maleic acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(実施例10)
ミノキシジル1g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、リン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 10)
1 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of phosphoric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(実施例11)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、クエン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 11)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of citric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(実施例12)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、乳酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 12)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of lactic acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain an external composition having a pH of 6.0.
(実施例13)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、酒石酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Example 13)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of tartaric acid, 20 g of purified water, and ethanol were added to bring the total amount to 100 g.
(比較例1)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、ポリエチレングリコール400 15g、リン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.3の外用組成物を得た。
(Comparative example 1)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of polyethylene glycol 400, an appropriate amount of phosphoric acid, 20 g of purified water, and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.3.
(比較例2)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、dl-リンゴ酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌して外用組成物を調製した。
(Comparative example 2)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of dl-malic acid, 20 g of purified water and ethanol to bring the total amount to 100 g, and stirred for about 1 hour to prepare a composition for external use.
(比較例3)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、ホウ酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌して外用組成物を調製した。
(Comparative Example 3)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of boric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to prepare a composition for external use.
(比較例4)
ミノキシジル5g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、グルコン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Comparative Example 4)
5 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of gluconic acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(比較例5)
ミノキシジル1g、ピリドキシン塩酸塩0.05g、プロピレングリコール15g、グルコン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Comparative Example 5)
1 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of propylene glycol, an appropriate amount of gluconic acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(比較例6)
ミノキシジル1g、ピリドキシン塩酸塩0.05g、ポリエチレングリコール400 15g、リン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Comparative Example 6)
1 g of minoxidil, 0.05 g of pyridoxine hydrochloride, 15 g of polyethylene glycol 400, an appropriate amount of phosphoric acid, 20 g of purified water, and ethanol to bring the total amount to 100 g, and stirred for about 1 hour to obtain a composition for external use with a pH of 6.0.
(比較例7)
ミノキシジル1g、プロピレングリコール15g、リン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Comparative Example 7)
1 g of minoxidil, 15 g of propylene glycol, an appropriate amount of phosphoric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain an external composition having a pH of 6.0.
(比較例8)
ミノキシジル5g、プロピレングリコール15g、クエン酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.1の外用組成物を得た。
(Comparative Example 8)
5 g of minoxidil, 15 g of propylene glycol, an appropriate amount of citric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain an external composition having a pH of 6.1.
(比較例9)
ミノキシジル5g、プロピレングリコール15g、乳酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Comparative Example 9)
5 g of minoxidil, 15 g of propylene glycol, an appropriate amount of lactic acid, 20 g of purified water, and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain a composition for external use having a pH of 6.0.
(比較例10)
ミノキシジル5g、プロピレングリコール15g、酒石酸適量、精製水20g、エタノールで全量を100gとし、約1時間撹拌してpH6.0の外用組成物を得た。
(Comparative Example 10)
5 g of minoxidil, 15 g of propylene glycol, an appropriate amount of tartaric acid, 20 g of purified water and ethanol were added to bring the total amount to 100 g, and the mixture was stirred for about 1 hour to obtain an external composition having a pH of 6.0.
<試験例1:析出試験-1>
実施例1、及び比較例1に関し、ガラスシャーレ上に外用組成物を各々100μL滴下し、24時間後にミノキシジル由来の結晶析出を目視で評価した。試験は3回実施した。
<Test Example 1: Precipitation Test-1>
Regarding Example 1 and Comparative Example 1, 100 μL of each topical composition was dropped onto a glass petri dish, and minoxidil-derived crystal precipitation was visually evaluated after 24 hours. The test was performed in triplicate.
試験の結果、多価アルコールとしてポリエチレングリコールを配合した比較例1と比べ、本発明の多価アルコールを用いた実施例1では、ミノキシジル由来の結晶析出が3回とも抑制されていた。 As a result of the test, in comparison with Comparative Example 1 in which polyethylene glycol was blended as the polyhydric alcohol, in Example 1 using the polyhydric alcohol of the present invention, minoxidil-derived crystal precipitation was suppressed all three times.
<試験例2:析出試験-2>
実施例10~13及び比較例6~10に関し、ガラスシャーレ上に外用組成物を各々100μL滴下し、24時間後にミノキシジル由来の結晶析出を目視で評価した。
<Test Example 2: Precipitation Test-2>
Regarding Examples 10 to 13 and Comparative Examples 6 to 10, 100 μL of each topical composition was dropped onto a glass petri dish, and after 24 hours, minoxidil-derived crystal precipitation was visually evaluated.
試験の結果、多価アルコールとしてポリエチレングリコールを配合した比較例6と比べ、本発明の多価アルコールを用いた実施例10では、ミノキシジル由来の結晶析出が抑制されていた。また、ピリドキシン塩酸塩を配合していない比較例7と比べ、本発明のピリドキシン塩酸塩を配合している実施例10では、ミノキシジル由来の結晶析出が抑制されていた。 As a result of the test, minoxidil-derived crystal precipitation was suppressed in Example 10 using the polyhydric alcohol of the present invention as compared with Comparative Example 6 in which polyethylene glycol was blended as the polyhydric alcohol. In addition, as compared with Comparative Example 7, which did not contain pyridoxine hydrochloride, minoxidil-derived crystal precipitation was suppressed in Example 10, which contained pyridoxine hydrochloride of the present invention.
さらに、本発明の異なる種類の酸を用いた製剤でも同様に、ミノキシジル由来の結晶析出が抑制されていた(実施例11~13及び比較例8~10)。 Furthermore, the precipitation of minoxidil-derived crystals was similarly suppressed in formulations using different kinds of acids of the present invention (Examples 11 to 13 and Comparative Examples 8 to 10).
<試験例3:ローション剤の調製試験>
実施例1~10、及び比較例2~5に関し、ローション剤の調製試験を実施した。調製後、ビーカー内のローション剤を目視で確認し、沈殿物のない澄明な製剤が得られたものを○、ローション剤中に沈殿物が生じたものを×とした。結果を表1に示す。
<Test Example 3: Preparation test of lotion>
For Examples 1 to 10 and Comparative Examples 2 to 5, lotion preparation tests were conducted. After preparation, the lotion in the beaker was visually checked, and the case where a clear formulation without sediment was obtained was rated as ◯, and the case where sediment was generated in the lotion was rated as x. Table 1 shows the results.
<試験例4:ピリドキシン塩酸塩の安定性試験>
実施例1~10、及び比較例4~5に関し、ピリドキシン塩酸塩の安定性試験を実施した。安定性試験は、各組成物を65℃の恒温器で2週間静置した後、ピリドキシン塩酸塩の含量を液体クロマトグラフィーで定量することにより行った。調製直後のピリドキシン塩酸塩の含量と比較し、ピリドキシン塩酸塩の低下が0~5%であったものを◎、6%~7%であったものを○、8~9%であったものを△、10%以上低下したものを×とした。結果を表1に示す。
<Test Example 4: Stability test of pyridoxine hydrochloride>
A stability test of pyridoxine hydrochloride was performed for Examples 1-10 and Comparative Examples 4-5. A stability test was performed by allowing each composition to stand in a thermostat at 65° C. for 2 weeks, and then quantifying the content of pyridoxine hydrochloride by liquid chromatography. Compared to the content of pyridoxine hydrochloride immediately after preparation, ⊚ indicates that the decrease in pyridoxine hydrochloride was 0 to 5%, ◯ indicates that it decreased by 6% to 7%, and 8 to 9% decreases. △, and those with a decrease of 10% or more were evaluated as ×. Table 1 shows the results.
表1から明らかなように、本発明の酸を用いた実施例1~10は、配合成分が全て溶解し、沈殿物のない澄明なローション剤が得られた。一方、酸のうちリンゴ酸又はホウ酸を用いた場合は調製後のローション剤中に沈殿物が生じた(比較例2、3)。
また、酸としてグルコン酸を用いた比較例4及び5は、ローション剤を調製することはできたものの、ピリドキシン塩酸塩の含量が顕著に低下した。一方、本発明の酸を用いた実施例1~10のローション剤はピリドキシン塩酸塩の含量低下は10%よりも低かった。特に、リン酸、塩酸、酢酸、硫酸、又は硝酸を用いた場合は、ピリドキシン塩酸塩の含量低下を5%以下に抑えることができ、好ましい結果であった。
As is clear from Table 1, in Examples 1 to 10 using the acid of the present invention, all the ingredients were dissolved and a clear lotion without sediments was obtained. On the other hand, when malic acid or boric acid was used among the acids, a precipitate was formed in the lotion after preparation (Comparative Examples 2 and 3).
In Comparative Examples 4 and 5, in which gluconic acid was used as an acid, lotions could be prepared, but the content of pyridoxine hydrochloride was significantly reduced. On the other hand, the lotions of Examples 1 to 10 using the acid of the present invention showed less than 10% decrease in pyridoxine hydrochloride content. In particular, when phosphoric acid, hydrochloric acid, acetic acid, sulfuric acid, or nitric acid was used, the decrease in pyridoxine hydrochloride content could be suppressed to 5% or less, which was a favorable result.
本発明により、ピリドキシンを配合したミノキシジル含有外用組成物において、塗布した後に生じる可能性のあるミノキシジル由来の析出を抑制し、外用組成物中の沈殿生成を抑制し、かつピリドキシン及び/又はその塩の安定性の低下を抑制した、優れたミノキシジル含有外用組成物を提供することが可能になった。 According to the present invention, in a minoxidil-containing external composition containing pyridoxine, minoxidil-derived precipitation that may occur after application is suppressed, precipitation in the external composition is suppressed, and pyridoxine and / or a salt thereof are suppressed. It has become possible to provide an excellent minoxidil-containing topical composition that suppresses a decrease in stability.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023174204A JP2023171964A (en) | 2016-01-22 | 2023-10-06 | Composition for external use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016010480 | 2016-01-22 | ||
JP2016010480 | 2016-01-22 | ||
JP2016180098 | 2016-09-15 | ||
JP2016180098 | 2016-09-15 | ||
JP2020198442A JP2021028347A (en) | 2016-01-22 | 2020-11-30 | Composition for external use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020198442A Division JP2021028347A (en) | 2016-01-22 | 2020-11-30 | Composition for external use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023174204A Division JP2023171964A (en) | 2016-01-22 | 2023-10-06 | Composition for external use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022177246A true JP2022177246A (en) | 2022-11-30 |
Family
ID=61767324
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017005531A Pending JP2018048105A (en) | 2016-01-22 | 2017-01-17 | Composition for external use |
JP2018137559A Active JP7070193B2 (en) | 2016-01-22 | 2018-07-23 | External composition |
JP2020198443A Pending JP2021028348A (en) | 2016-01-22 | 2020-11-30 | Composition for external use |
JP2020198442A Pending JP2021028347A (en) | 2016-01-22 | 2020-11-30 | Composition for external use |
JP2022153557A Pending JP2022177246A (en) | 2016-01-22 | 2022-09-27 | Composition for external use |
JP2023174204A Pending JP2023171964A (en) | 2016-01-22 | 2023-10-06 | Composition for external use |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017005531A Pending JP2018048105A (en) | 2016-01-22 | 2017-01-17 | Composition for external use |
JP2018137559A Active JP7070193B2 (en) | 2016-01-22 | 2018-07-23 | External composition |
JP2020198443A Pending JP2021028348A (en) | 2016-01-22 | 2020-11-30 | Composition for external use |
JP2020198442A Pending JP2021028347A (en) | 2016-01-22 | 2020-11-30 | Composition for external use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023174204A Pending JP2023171964A (en) | 2016-01-22 | 2023-10-06 | Composition for external use |
Country Status (1)
Country | Link |
---|---|
JP (6) | JP2018048105A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018048105A (en) * | 2016-01-22 | 2018-03-29 | 大正製薬株式会社 | Composition for external use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001502A1 (en) * | 1986-09-05 | 1988-03-10 | The Upjohn Company | Sebum-dissolving nonaqueous minoxidil formulation |
JPH09249539A (en) * | 1996-03-18 | 1997-09-22 | Lion Corp | Hair cosmetic |
JPH11263727A (en) * | 1997-12-03 | 1999-09-28 | Taisho Pharmaceut Co Ltd | Minoxidil formulated liquid preparation composition |
AUPP310798A0 (en) * | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
WO2001076541A1 (en) * | 2000-04-07 | 2001-10-18 | Taisho Pharmaceutical Co. Ltd. | Hair growth stimulant compositions |
JP2002029935A (en) * | 2000-07-17 | 2002-01-29 | Taisho Pharmaceut Co Ltd | Hair-growing agent |
US7442369B1 (en) * | 2000-08-09 | 2008-10-28 | Mcneil Ab | Compositions of minoxidil |
JP2002226329A (en) * | 2001-02-02 | 2002-08-14 | Taisho Pharmaceut Co Ltd | Hair grower |
JP2002326913A (en) * | 2001-02-27 | 2002-11-15 | Taisho Pharmaceut Co Ltd | Hair growing composition |
JP2005314323A (en) * | 2004-04-30 | 2005-11-10 | Sato Pharmaceutical Co Ltd | Hair growth formulation |
JP2009091325A (en) * | 2007-10-11 | 2009-04-30 | Rohto Pharmaceut Co Ltd | Hair growth agent |
JP6244101B2 (en) * | 2013-04-24 | 2017-12-06 | ロート製薬株式会社 | Minoxidil-containing external composition |
JP2018048105A (en) * | 2016-01-22 | 2018-03-29 | 大正製薬株式会社 | Composition for external use |
-
2017
- 2017-01-17 JP JP2017005531A patent/JP2018048105A/en active Pending
-
2018
- 2018-07-23 JP JP2018137559A patent/JP7070193B2/en active Active
-
2020
- 2020-11-30 JP JP2020198443A patent/JP2021028348A/en active Pending
- 2020-11-30 JP JP2020198442A patent/JP2021028347A/en active Pending
-
2022
- 2022-09-27 JP JP2022153557A patent/JP2022177246A/en active Pending
-
2023
- 2023-10-06 JP JP2023174204A patent/JP2023171964A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7070193B2 (en) | 2022-05-18 |
JP2021028347A (en) | 2021-02-25 |
JP2018162320A (en) | 2018-10-18 |
JP2018048105A (en) | 2018-03-29 |
JP2023171964A (en) | 2023-12-05 |
JP2021028348A (en) | 2021-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7099581B2 (en) | External composition | |
JP2022173381A (en) | Composition for external use | |
JP2023171964A (en) | Composition for external use | |
JP6819275B2 (en) | Topical solution | |
JP7067581B2 (en) | Lotion | |
JP2024026455A (en) | External composition | |
JP6825354B2 (en) | Topical composition | |
JP6528466B2 (en) | Composition for external use | |
JP6424815B2 (en) | Composition for external use | |
JP5780690B2 (en) | Hair growth composition | |
JP7124435B2 (en) | external composition | |
JP2023060220A (en) | Composition for external use | |
JP2023099672A (en) | External pharmaceutical composition | |
JP6821916B2 (en) | Topical composition | |
JP2019137626A (en) | Hair restorer | |
JP2020045338A (en) | External composition | |
JP2021167298A (en) | Pharmaceutical composition for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240202 |